You are in: Instituto de Salud Carlos III >> International >> Framework Programme >> Joint financing for FP7 (ERA-NET and Article 185)

Framework Programme

Joint financing for FP7 (ERA-NET and Article 185)

Joint financing for FP7 (ERA-NET and Article 185)

ERA-NET is a funding scheme of the European Commission for the implementation of joint activities with funds from national and regional R&D programmes. The initiative was launched in 2002, during the course of FP6, with a view to strengthening the European Research Area in topics with high European added value. It is materialised through coordinated research activities conducted nationally or regionally and through reciprocal access to national and regional programmes.

The Instituto de Salud Carlos III participates in ERA-Net activities in the areas of neurosciences, nanomedicine, rare diseases, and paediatrics, all of which are strategic areas of interest for the EU given the extent to which they affect public health and the economic growth of the European Union.

  • ERA-NET Neuron: The aim of the Network of European Funding for Neuroscience Research is to link the activities of 16 national research funding programmes in the field of nervous system diseases and neurosciences.
  • EuroNanoMed: This ERA-Net initiative brings together 24 partners from 18 countries and regions. It aims to foster the competitiveness of the European Union in the area of nanomedicine through the support of trans-national collaborative and multidisciplinary research projects. Nanomedicine is the application of nanotechnology to medicine and healthcare. It takes advantage of the physical, chemical and biological properties of materials at the nanometer scale to be used for diagnosis, treatment and follow-up of diseases.
  • E-Rare: It aims to promote European research in rare diseases through joint development and management of national and regional programmes in this field. It brings together 10 partners from eight countries.
  • PrioMedChild: It is a programme to promote the use of research results in developing priority drugs for use in paediatrics. It is comprised of 13 partners.

 

Article 185 initiatives

Article 185 of the Treaty of Lisbon envisages EC participation in the national R&D programmes adopted by Member States, and in the infrastructure needed for the execution of those programmes. Initiatives emerging under the protection of this article represent a more advanced stage of the ERA-Net scheme and involve a firm commitment to research integration by Member States participating in them.

The Instituto de Salud Carlos III takes part in two of the initiatives currently in place: European and Developing Countries Clinical Trials Partnership (EDCTP) and Ambient Assisted Living (AAL).

  • EDCTP is an alliance of 14 Member States, Norway, Switzerland and 47 African countries in the fight against HIV/AIDS, malaria and tuberculosis in sub-Saharan Africa. Among other objectives, it aims to accelerate the innovation and development of drugs, vaccines and microbicides to fight these diseases using clinical trials in the region.
  • AAL  is an ambitious programme to improve the quality of life of older adults through the use of new information and communication technologies. It is a joint initiative involving 20 Member States and three Associated States.

® Instituto de Salud Carlos III